Charles River Laboratories International Stock News

Charles River (CRAI) has a diversified business with service offerings across areas of functional expertise, client base and geographical regions.

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

LTX, Broadridge Financial Solutions, Inc.’s artificial intelligence (AI)-driven digital trading platform, has completed a successful integration with the Charles River Investment Management Solution (Charles River IMS). The complete integration enables Charles River’s order and execution management system (OEMS) users to better access aggregated liquidity and leverage transparency and price discovery within their existing workflows through their existing […] The post Broadridge’s LTX Completes Integration with Charles River Development appeared first on AiThority .

Investors are optimistic about Charles River (CRL) on robust demand in Biologics Testing Solutions and Microbial Solutions businesses.

Charles River's (CRAI) fourth-quarter 2021 revenues improve year over year.

The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.

Street firms are having different reactions to Charles River Laboratories'' (CRL) Q4 2021 results, in which it beat on the top and bottom lines.

Charles River Laboratories International, Inc. (CRL) CEO James Foster on Q4 2021 Results - Earnings Call Transcript

Charles River Laboratories International Inc''s (NYSE: CRL ) Q4 sales increased 14.4% Y/Y to $905.1 million , beating the consensus of $888.27 million. Acquisitions contributed 5.9% to consolidated fourth-quarter revenue growth. Organic revenue growth was 10.5%, driven by contributions from all three business segments. Adjusted EPS reached $2.49 higher than $2.39 posted a year ago and … Full story available on Benzinga.com

Charles River Laboratories International <> stock declined following its Q4 results, which beat analysts'' estimates, and reaffirming its 2022 Guidance.Q4 total revenue increased…

Shares of Charles River Laboratories (CRL) are struggling today even though the company posted Q4 2021 results that beat on the top and bottom lines.

Robust demand for research models, particularly in China, as well as higher revenues from research model services aid Charles River (CRL) in Q4.

Charles River Laboratories press release (CRL): Q4 Non-GAAP EPS of $2.49 beats by $0.06.Revenue of $905.05M (+14.4% Y/Y) beats by $16.78M.Reaffirms 2022 Guidance: Revenue growth 13.0%…